Asterias Biotherapeutics (AST) Misses Q3 EPS by 7c

Asterias Biotherapeutics (NYSE: AST) reported Q3 EPS of ($0.24), $0.07 worse than the analyst estimate of ($0.17). Revenue for the quarter came in at $2.1 million versus the consensus estimate of $1.5 million.

As of September 30, 2016, the company's cash, cash equivalents and available-for-sale securities totaled $33.9 million, which management believes will be sufficient to fund operations through the third quarter of 2017.

For earnings history and earnings-related data on Asterias Biotherapeutics (AST) click here.

You May Also Be Interested In

• Tesla touts acceleration of new models, but Q1 results fall short of estimates
• EQT Corp. (EQT) Tops Q1 EPS by 17c; offers outlook
• Visa (V) earnings and revenue exceed estimates in Q2, shares rise